Scientists test re-engineered immune cells to fight deadly childhood brain cancer

NCT ID NCT04196413

Summary

This early-phase study is testing whether a patient's own immune cells can be modified in a lab to recognize and attack a specific aggressive type of brain or spinal cord tumor. The main goals are to see if these modified cells (called GD2CART) can be reliably made and given safely to children and adults (ages 2-60) with these hard-to-treat cancers. Researchers will also gather early information on whether the treatment helps control the disease.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOMA OF SPINAL CORD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Lucile Packard Children's Hospital (LPCH)

    RECRUITING

    Stanford, California, 94304, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.